Key statistics
As of last trade Ascletis Pharma Inc (2VJ:FRA) traded at 0.184, -14.02% below its 52-week high of 0.214, set on Feb 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.204 |
---|---|
High | 0.204 |
Low | 0.184 |
Bid | 0.204 |
Offer | 0.232 |
Previous close | 0.191 |
Average volume | 0.00 |
---|---|
Shares outstanding | 977.12m |
Free float | 251.12m |
P/E (TTM) | -- |
Market cap | 1.80bn HKD |
EPS (TTM) | -0.2674 HKD |
Data delayed at least 15 minutes, as of Nov 22 2024 08:15 GMT.
More ▼
Press releases
- Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
- Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity
- Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity